Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 22, 2007

Merck & Co’s Japanese Subsidiary Inks Oncology and Metabolic Drug Discovery Deal with MerLion

  • MerLion Pharmaceuticals and Merck Banyu, the Japanese subsidiary of Merck & Co., signed a two-year drug discovery and licensing agreement.

    Under the new collaboration, MerLion and Banyu will identify new drug candidates from MerLion's natural product sample collection utilizing a range of validated targets in oncology and metabolic disease. MerLion will receive upfront payments and predefined milestones and royalties for the licensing of collaborative discoveries.

    MerLion has also extended its four-year agreement based on infectious disease targets with Merck & Co.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »